The drug can stop the process of replication of coronavirus once it enters the body of the host ensuring to eliminate the spread of the virus.
The drug can stop the process of replication of coronavirus once it enters the body of the host ensuring to eliminate the spread of the virus.|Representational image
CORONAVIRUS UPDATES

COVID-19 drug favipiravir approved for clinical trials in India

The drug can stop the process of replication of coronavirus once it enters the body of the host ensuring to eliminate the spread of the virus.

Team EastMojo

Team EastMojo

The wonder drug favipiravir touted to cure infected cases of coronavirus has finally been approved by the Drug Controller of India for clinical trial in the country. The favipiravir drug developed indigenously by CSIR laboratory will be used to treat coronavirus patients.

According to reports, the Indian Institute of Chemical Technology (IICT), Hyderabad has developed the technology to make the drug favipiravir.

A private company will now tie-up with hospitals for clinical trials so that the drug could be tested on patients admitted for treatment of COVID-19.

The drug is already being put to use in many countries such as China and Japan to treat influenza and this has currently shown promising effects in treating people infected with the coronavirus.

The drug can stop the process of replication of coronavirus once it enters the body of the host ensuring to eliminate the spread of the virus.

The Drug Controller of India has granted permission to conduct tests on critically ill COVID-19 patients at three major hospitals in the country.

For more such stories, follow us on Facebook, Twitter and Instagram. Activate Website Notifications to stay updated.

EastMojo
www.eastmojo.com